Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+Study

被引：0
|
作者：
Morgensztern, D. [1 ]
Cobo Dols, M. [2 ]
Ponce Aix, S. [3 ]
Postmus, P. E. [4 ]
Bennouna, J. [5 ]
Fischer, J. [6 ]
Vidal, O. [7 ]
Stewart, D. [8 ]
Fasola, G. [9 ]
Weaver, J. [10 ]
Wolfsteiner, M. [11 ]
Ong, T. J. [10 ]
Govindan, R. [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Hosp Reg Univ Carlos Haya, Gen Hosp, Malaga, Spain
[3] Unidad Invest Clin Canc Pulmon H12O Cnio, Madrid, Spain
[4] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[5] Ctr Rene Gauducheau, Ctr Lutte Canc Nantes Atlantique, Nantes, Loire Atlantiqu, France
[6] Lungenklin Lowenstein, Lowenstein, Baden Wurttembe, Germany
[7] Univ Politecn La Fe, Valencia, Spain
[8] Ottawa Hosp, Ottawa, ON, Canada
[9] Univ Hosp Santa Maria Della Misericordia, Udine, Italy
[10] Celgene Corp, Summit, NJ USA
[11] Pra Hlth Sci, Lenexa, KS USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
nab-paclitaxel; Second-line; CC-486;
D O I：
10.1016/j.jtho.2017.09.460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 03.01
引用
收藏
页码：S1806 / S1807
页数：2
相关论文
共 50 条
  • [31] Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
    Nan Zhou
    Xiaofen Li
    Yu Yang
    Sirui Tan
    Shunyu Zhang
    Qiyue Huang
    Hongfeng Gou
    BMC Cancer, 23
  • [32] Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) plus carboplatin (C): Interim results from the ABOUND. 70+study
    Weiss, J.
    Kim, E.
    Amiri, K. I.
    Anderson, E.
    Dakhil, S.
    Haggstrom, D.
    Jotte, R.
    Konduri, K.
    Modiano, M.
    Ong, T. J.
    Sanford, A.
    Smith, D.
    Socoteanu, M.
    Goldman, J.
    Langer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
    Merz, Valeria
    Cavaliere, Alessandro
    Messina, Carlo
    Salati, Massimiliano
    Zecchetto, Camilla
    Casalino, Simona
    Milella, Michele
    Caffo, Orazio
    Melisi, Davide
    CANCERS, 2020, 12 (05)
  • [34] Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience
    Okunaka, Mashiro
    Kotani, Daisuke
    Demachi, Ken
    Kawazoe, Akihito
    Yoshino, Takayuki
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [35] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [36] A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
    Nio, K.
    Iguchi, H.
    Shimokawa, M.
    Shirakawa, T.
    Koga, F.
    Ueda, Y.
    Nakazawa, J.
    Komori, A.
    Arima, S.
    Fukahori, M.
    Makiyama, A.
    Taguchi, H.
    Honda, T.
    Shibuki, T.
    Ide, Y.
    Ureshino, N.
    Mizuta, T.
    Mitsugi, K.
    Otsuka, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1314 - S1314
  • [37] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [38] nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm
    Thomas, Michael
    Page, Ray
    Gressot, Laurent
    Danie, Davey
    Morgensztern, Daniel
    Villaflor, Victoria
    Aix, Santiago
    Ong, Teng
    Trunova, Nataliya
    Spigel, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S906 - S906
  • [39] Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer
    Kokkali, S.
    Drizou, M.
    Tripodaki, E.
    Stefanou, D.
    Magou, E.
    Zylis, D.
    Kapiris, M.
    Nasi, D.
    Georganta, C.
    Ardavanis, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC
    Thomas, Michael
    Page, Ray
    Gressot, Laurent
    Daniel, Davey
    Morgensztern, Daniel
    Levy, Benjamin
    Hussein, Maen
    Razaq, Mohammad
    Villaflor, Victoria M.
    Aix, Santiago P.
    Sivarajan, Kulumani
    Engel-Riedel, Walburga
    Staib, Peter
    Ko, Amy
    Ong, Teng J.
    Trunova, Nataliya
    Spigell, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S269 - S269
12345